Last modified: 22 May 2019 17:07
Modern biotechnology is absolutely dependent upon our increasingly sophisticated ability to use microbial and mammalian host cells as factories to produce high quantities of protein pharmaceuticals, e.g. insulin. Increasingly, cells engineered with multiple foreign genes are also being used to drive small molecule drug production. This course will explore how such heterologous protein expression processes can be engineered and optimised to drive efficient synthesis of the next generation medicines on which healthcare systems are increasingly depending.
|Session||First Sub Session||Credit Points||15 credits (7.5 ECTS credits)|
|Campus||Old Aberdeen||Sustained Study||No|
This course will provide a detailed description of a range of modern biotechnological processes and principles that underpin a range of protein expression systems used in the manufacture of modern medicines and protein biologics. The course will explain the challenges in overexpressing foreign proteins in host cells, and how those challenges are overcome to maximise yield, while optimising downstream purification and processing of the expressed protein. The course will introduce a range of heterologous expression systems, and explore their relative advantages.
The knowledge and skills this course will equip you with will be directly relevant to a range of bioscience career options, including employment in the rapidly expanding biotechnology sector.
Information on contact teaching time is available from the course guide.
Practical report (50%); Examination (50%).
Resit: viva exam with two academic staff.
There are no assessments for this course.
Feedback provided via on-line marking platforms within MyAberdeen